• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Business

TFF and Felix Biotechnology sign letter of intent for proposed development of inhaled bacteriophage for the treatment of lung infections

TFF Pharmaceuticals and Felix Biotechnology have signed a non-binding letter of intent for a proposed agreement regarding development of an inhaled dry powder bacteriophage for the treatment of lung infections. Felix would need to successfully complete a Series A financing before entering into a definitive agreement, which would provide for Felix to make an upfront … [Read more...] about TFF and Felix Biotechnology sign letter of intent for proposed development of inhaled bacteriophage for the treatment of lung infections

TFF and Augmenta Bioworks partner on inhaled mAbs for COVID-19

TFF Pharmaceuticals and Augmenta Bioworks have announced a an agreement to collaborate on development of inhaled dry powder monoclonal antibodies (mAbs) for the treatment of COVID-19 based on Augmenta’s mAbs and TFF's thin film freezing particle technology. TFF will also have an option on two more Augmenta mAbs, which it could develop for the treatment of other … [Read more...] about TFF and Augmenta Bioworks partner on inhaled mAbs for COVID-19

Opiant switches to Aptar’s UDS for delivery of its intranasal nalmefene

Opiant Pharmaceuticals said that it has terminated an agreement for the use of Bespak's Unidose Xtra device for delivery of its OPNT003 intranasal nalmefene for the treatment of opioid overdose and has entered into a new agreement with Aptar Pharma for the use Aptar’s Unit Dose System (UDS) to deliver OPNT003. Opiant already uses the UDS for delivery of its Narcan … [Read more...] about Opiant switches to Aptar’s UDS for delivery of its intranasal nalmefene

Experic adds TFF thin film freezing manufacturing capability

CDMO Experic is adding a thin film freezing manufacturing line based on technology owned by TFF Pharmaceuticals at its Cranbury, NJ, USA cGMP facility, according to TFF. Completion of Experic's TFF line, which adds a third cGMP manufacturing site for TFF, is expected in the second quarter of 2021. In September 2020, TFF announced that it will advance its … [Read more...] about Experic adds TFF thin film freezing manufacturing capability

Synspira gets additional CF Foundation funding for development of inhaled glycopolymer

The Cystic Fibrosis Foundation (CFF) has awarded Synspira Therapeutics up to $14 million in additional funding for development of two Synspira candidates including SNSP113, an inhaled polycationic glycopolymer for the treatment of CF. The foundation had previously awarded Synspira $8.55 million in 2017. SNSP113, which is currently in Phase 2 development, received … [Read more...] about Synspira gets additional CF Foundation funding for development of inhaled glycopolymer

US PTAB institutes inter partes review of Tyvaso patent

Liquidia Technologies said that the US Patent Trial and Appeal Board (PTAB) has issued decisions on two patents related to Tyvaso treprostinil inhalation solution, which is marketed by United Therapeutics for the treatment of pulmonary arterial hypertension (PAH). Liquidia filed petitions with the US Patent and Trademark Office seeking to invalidate the two patents in … [Read more...] about US PTAB institutes inter partes review of Tyvaso patent

Zydus Cadila launches Forglyn formoterol / glycopyrrolate MDI in India

Zydus Cadila has announced the launch of its Forglyn formoterol fumarate / glycopyrrolate MDI for the treatment of COPD India. According to Zydus Cadila, the inhaler, which was developed at the company's Pharmaceutical Technology Center, will cost ₹495 (~$7) per pack. Cadila Healthcare Managing Director Sharvil Patel commented, "Our focus has always been on helping … [Read more...] about Zydus Cadila launches Forglyn formoterol / glycopyrrolate MDI in India

Irish consortium to develop inhaled exosomes therapy for ARDS, COPD

A consortium formed by Irish biotech OmniSpirant, nebulizer maker Aerogen, and the National University of Ireland Galway has received a €11.6 million grant from Ireland's Disruptive Technologies Innovation Fund for development of OS002, an inhaled exosomes therapy for the treatment of acute respiratory distress syndrome (ARDS) as well as for COPD. The 3-year project … [Read more...] about Irish consortium to develop inhaled exosomes therapy for ARDS, COPD

Teva launches Aermony RespiClick in Canada

Teva Canada has launched the Aermony RespiClick fluticasone propionate DPI for the treatment of asthma, the company said. The inhaler will be available in 55 mcg, 113 mcg, and 232 mcg per actuation versions. According to the Health Canada web site, Aermony Respiclick was approved in 2017, the same year that ArmonAir Resplick fluticasone propionate was approved in … [Read more...] about Teva launches Aermony RespiClick in Canada

Starpharma raises A$45 million to be used in part for development of astodrimer sodium nasal spray for COVID-19

Starpharma said that it has raised A$45 million and expects to raise another A$5 million from Australian and international investors, with proceeds to be used for development of its SPL7013 astodrimer sodium nasal spray for the treatment of COVID-19 as well as for other candidates. The company recently announced that the nasal spray inactivated almost 100% of … [Read more...] about Starpharma raises A$45 million to be used in part for development of astodrimer sodium nasal spray for COVID-19

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 42
  • Page 43
  • Page 44
  • Page 45
  • Page 46
  • Interim pages omitted …
  • Page 152
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Intertek banner
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews